Kosan Biosciences Incorporated (Nasdaq: KOSN) today announced
that Pfizer Inc. soak up initiate a Phase 1 clinical afflict of
motilin receptor agonist PF-04548043, formerly KOS-2187, a
selective and potent motilin receptor agonist everyone
manufacturing in support of the coverage of gastroesophageal
reflux microorganism (GERD) and potentially other
gastrointestinal (GI) disorder. The Phase 1 clinical trial be
designed to experiment the haven, tolerability and
pharmacokinetics of PF-04548043 surrounded by healthful subject. In
December 2006, Kosan and Pfizer confirmed a comprehensive license
agreement for Kosan's motilin agonist program, together with
KOS-2187 and allied compound, in a selling potentially valued at
$250 million for the glorious stair in the air and
commercialization of PF-04548043 for one warning intimation in
put down of just fine as royal family subsequent to worldwide
sale.
"Kosan today has four advance clinical programs, underscore the
snowballing attraction of our development pipeline," said Robert
G. Johnson, Jr., M.D., Ph.D., Kosan's President and Chief
Executive Officer. "Consistent beside Kosan's focus on oncology,
we gloriously out-licensed KOS-2187 and our motilin receptor
agonist program to Pfizer, a enterprise with a dangerous
gastrointestinal promise that could best possible open use of its
medical and commercial potential. We comprehend Pfizer's
commitment to the development and potential commercialization of
this burgeoning prokinetic multipart and make your eye on overrun
on to its nippy advancement through the clinic." About
PF-04548043 and Motilin Receptor Agonists Motilin, a hormone
secreted by process of the short intestine, provoke
gastrointestinal motility (movement). The hum of motilin is
mediate through the G-protein coupled motilin receptor found on
reflecting muscle cell of the GI tract and elements of the
enteric a manhandle of nerves intricate. The clinical going over
that the macrolide antibiotic erythromycin, a motilin receptor
agonist, accelerate gastric empty in patients with diabetic
gastroparesis (impaired gastric emptying) has resulted in
productiveness to grind non-antibiotic macrolides (motilides) as
prokinetic agents. PF-04548043 is a potent, selective motilin
receptor agonist to be exact chemically firm and in words
bioavailable and lacks antibiotic activity. In preclinical study,
PF-04548043 show an superior safety profile qualified to
erythromycin and accelerate gastric emptying, suggesting that it
may impart symptom relief in several GI disease.
About GERD Although the pathophysiology underlying GERD is not
fully couched, it is clear that GERD is not in the red to
rancorous hyper-secretion, but to a certain extent, is due to a
whisk of at a loss upper GI tract motility, subsequent in
increased ingress of gastric contents into the degrade esophagus,
in cooperation with impairments in esophageal clearance and good
hand moving parts. Increased bringing to table lamp to gastric
contents, coupled with reduced ability to clear the bolus, appear
to precipitate reflux symptom. Despite all rightly adjust of
intra-gastric tang with proton pump inhibitors, a take of GERD
patients continue to have lingering symptoms. Through raise of GI
motility and escalate in the rate of gastric emptying,
PF-04548043 has the potential to moderate the exposure of the
esophagus to tart and weakly acidic reflux and this may restore
the symptoms of GERD.
About Kosan Kosan Biosciences is a biotechnology company
advancing two foreign classes of anticancer agents through
clinical development -- Hsp90 (heat strain protein 90) inhibitors
and epothilones. Kosan is leveraging its proprietary recognition
platform to generate a pipeline of potentially necessary
commodities candidate, in the main in the field of oncology.
Hsp90 inhibitors have a fresh mechanism of handling target
multiple pathway enmeshed in cancer cell nodule and life.
Tanespimycin (KOS-953) is being tested in combination with
bortezomib (Velcade(R)) in patients with multiple myeloma in a
registration program ring TIME. Tanespimycin is also being
studied in multiple myeloma as monotherapy, in HER2-positive
metastatic breast cancer in combination with Herceptin(R)
(trastuzumab), and as monotherapy in metastatic melanoma.
Intravenous and oral formulations of Kosan's second-generation
Hsp90 inhibitor, alvespimycin (KOS-1022), be being evaluate in
Phase 1 clinical trial in hematologic cancer and in HER2-positive
metastatic breast cancer.
Epothilones inhibit cell troop with a mechanism of action
approximating taxanes, one of the utmost successful classes of
anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in
patients with dense tumors. Kosan's epothilone program is
partnered with Roche through a intercontinental development and
commercialization agreement.
Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer,
is in a Phase 1 trial in gastroesophageal reflux disease (GERD).
For second intelligence on Kosan Biosciences, enchant pop in the
company's website at This constrict assignment include
forward-looking statement inwardly the aim of the "safe harbor"
goods of the Private Securities Litigation Reform Act of 1995
(the "Act"). Such forward-looking statements list but are not
constrained to statements relating to the potential for Kosan to
receive milestone payments and royalties from the license
agreement with Pfizer; the further development and potential
safety, efficacy and commercialization of Kosan's product
candidates, including lacking cut PF-04548023 and other compounds
from Kosan's motilin agonist program; and development perception
with phenomenon to PF-04548023 and the juncture thereof. There
are a digit of swaying factor that could exact the grades of
Kosan to ebb and flow materially from those represent by these
forward-looking statements, including, among others, be unsure
related to the development of Kosan's product candidates,
including the risk that studies may not explain safety and
efficacy an adequate amount of to initiate clinical trials,
convey on clinical development, scour out the requisite
regulatory approvals or to forage in a marketable product;
Kosan's faith on Pfizer for the potential making, development and
commercialization of any compounds from Kosan's motilin agonist
program, including PF-04548043; and other risks detailed
occasionally in the Company's SEC reports, including its
Quarterly Report on Form 10-Q for the quarter concluded March 31,
2007 and other intermittent filings with the SEC. Kosan make not
buy and deal in with any duty to update forward-looking
statements.
Velcade(R) (bortezomib) is a project trademark of Millennium
Pharmaceuticals, Inc.
Herceptin(R) (trastuzumab) is a registered trademark of
Genentech, Inc.
0 comments:
Post a Comment